NCT01264783View on ClinicalTrials.gov

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Myocardial Infarct
Interventions
DRUG

RNS60

RNS60 for intravenous administration

DRUG

Placebo

0.9% normal saline for injection

Trial Locations (1)

66211

Quintiles, Inc., Overland Park

All Listed Sponsors
lead

Revalesio Corporation

INDUSTRY

NCT01264783 - Safety and Tolerability of RNS60 Given by IV to Healthy Subjects | Biotech Hunter | Biotech Hunter